Thirty-year visual acuity outcomes after plaque brachytherapy for posterior uveal melanoma.

Mean visual acuity declined from 0.34 logMAR (20/44) at diagnosis to 0.82 logMAR (20/132) at the last follow-up.

Among eyes beginning with ≥20/40, corresponding probabilities were 73%, 52%, 26%, and 8%.

Iodine 125 plaques (sHR [subdistribution hazard ratio]: 3.57 vs ruthenium 106; 95% CI: 2.43-5.23) independently predicted vision <20/200, while each additional millimetre of tumour-fovea distance was protective (sHR 0.90; 95% CI: 0.86-0.95).